Mostrar el registro sencillo del ítem

dc.contributor.authorRamos, L.*
dc.contributor.authorTeo-Loy, J.*
dc.contributor.authorBarreiro de Acosta, Manuel *
dc.date.accessioned2025-09-09T10:21:54Z
dc.date.available2025-09-09T10:21:54Z
dc.date.issued2023
dc.identifier.citationRamos L, Teo-Loy J, Barreiro-de Acosta M. Disease clearance in ulcerative colitis: Setting the therapeutic goals for future in the treatment of ulcerative colitis. Vol. 9, Frontiers in Medicine. Frontiers Media S.A.; 2023.
dc.identifier.issn2296-858X
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/63df0b036fdec82c4e7e0649
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21357
dc.description.abstractUlcerative colitis, one of the phenotypic patterns of inflammatory bowel disease, should be considered a progressive disease with an increased risk of complications if intestinal inflammation is not adequately controlled. The advent of new lines of treatment for this condition has changed and expanded the therapeutic goals to modify its natural history and evolution. The concept of "disease clearance" in ulcerative colitis aims to achieve clinical and biological remission as well as mucosal healing (endoscopic, histological, and in future molecular) in these patients. This review provides the available data on each of the goals of disease clearance in ulcerative colitis to be considered for application in clinical practice in the coming years.
dc.description.sponsorshipLR has received educational and travel grants and speaker fees from MSD, Pfizer, Abbvie, Takeda, Janssen, Shire Pharmaceuticals, Ferring, and Dr. Falk Pharma. MB-d has served as a speaker, consultant, and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Gilead, Celgene, Pfizer, Ferring, Faes Farma, Shire Pharmaceuticals, Falk Pharma, Chiesi, Gebro Pharma, Adacyte and Vifor Pharma.
dc.languageeng
dc.rightsAttribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleDisease clearance in ulcerative colitis: Setting the therapeutic goals for future in the treatment of ulcerative colitis
dc.typeArtigo
dc.authorsophosRamos, L.; Teo-Loy, J.; Barreiro-de Acosta, M.
dc.identifier.doi10.3389/fmed.2022.1102420
dc.identifier.sophos63df0b036fdec82c4e7e0649
dc.journal.titleFrontiers in Medicine*
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Dixestivo
dc.relation.projectIDMSD
dc.relation.projectIDPfizer
dc.relation.projectIDAbbvie
dc.relation.projectIDTakeda
dc.relation.projectIDJanssen
dc.relation.projectIDShire Pharmaceuticals
dc.relation.projectIDFerring
dc.relation.projectIDDr. Falk Pharma
dc.relation.projectIDKern Pharma
dc.relation.projectIDCelltrion
dc.relation.projectIDGilead
dc.relation.projectIDCelgene
dc.relation.projectIDFaes Farma
dc.relation.projectIDFalk Pharma
dc.relation.projectIDChiesi
dc.relation.projectIDGebro Pharma
dc.relation.projectIDAdacyte
dc.relation.projectIDVifor Pharma
dc.relation.publisherversionhttps://doi.org/10.3389/fmed.2022.1102420
dc.rights.accessRightsopenAccess*
dc.subject.keywordAS Santiago
dc.subject.keywordCHUS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo de Revisión
dc.volume.number9


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 International (CC BY 4.0)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International (CC BY 4.0)